Kazia Therapeutics Share Price (NASDAQ: KZIA)

$7.73

▲

0.43

(5.89%)

Last updated on August 23, 2025 at 1:28 AM IST

$₹

Check the interactive Kazia Therapeutics Stock chart to analyse performance

Kazia Therapeutics stock performance

as on August 23, 2025 at 1:28 AM IST

Today's Low:$7.60
Today's High:$7.73
$7.73
1.68%
Downside
Day's Volatility :1.68%
Upside
0.0%
52 Weeks Low:$2.86
52 Weeks High:$39.05
$7.73
63.0%
Downside
52 Weeks Volatility :92.68%
Upside
80.2%

Kazia Therapeutics Stock Returns

Period	Kazia Therapeutics Ltd	Index (Russel 2000)
3 Months	103.21%	0.0%
6 Months	75.47%	0.0%
1 Year	-57.79%	0.0%
3 Years	-91.06%	-8.6%

Kazia Therapeutics Ltd Key Stats

Check Kazia Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$7.3
Open	$7.6
Today's High	$7.73
Today's Low	$7.6
Market Capitalization	$9.9M
Today's Volume	$4.3K
52 Week High	$39.05
52 Week Low	$2.86
Revenue TTM	$2.5M
EBITDA	$-27.1M
Earnings Per Share (EPS)	$-28.85
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-3891.64%

Stock Returns calculator for Kazia Therapeutics Stock including INR - Dollar returns

The Kazia Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Kazia Therapeutics investment value today

Current value as on today

₹47,236

Returns

₹52,764

(-52.76%)

Returns from Kazia Therapeutics Stock

₹57,079 (-57.08%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Kazia Therapeutics Stock

-57%

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Kazia Therapeutics Stock from India on INDmoney has decreased by -57% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Kazia Therapeutics Ltd

Name
Holdings %
Name
Holdings %
Rhumbline Advisers
0.03%
GAMMA Investing LLC
0.02%

Analyst Recommendation on Kazia Therapeutics Stock

Rating

Trend

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Kazia Therapeutics(by analysts ranked 0 to 5 stars)

Kazia Therapeutics Share Price Target

What analysts predicted

Upside of 78.44%

Target:

$13.79

Current:

$7.73

Kazia Therapeutics share price target is $13.79, a slight Upside of 78.44% compared to current price of $7.73 as per analysts' prediction.

Kazia Therapeutics Stock Insights

Price Movement
In the last 7 days, KZIA stock has moved down by -5.4%
Increasing Revenue
Revenue is up for the last 2 quarters, 5.0 → 2.48M (in $), with an average increase of 100.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -3.43M → -17.95M (in $), with an average decrease of 77.3% per quarter
KZIA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.6% return, outperforming this stock by 124.4%
KZIA vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 105.6% return, outperforming this stock by 196.7%
Price to Sales
ForKZIA every $1 of sales, investors are willing to pay $2.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Kazia Therapeutics Ltd Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.1K	↓ 88.06%
Net Income	$-7.1M	↑ 70.06%
Net Profit Margin	-656.2K%	↓ 610158.93%

	FY20	Y/Y Change
Revenue	$731.0	↓ 32.2%
Net Income	$-8.6M	↑ 21.39%
Net Profit Margin	-1.2M%	↓ 518793.53%

	FY21	Y/Y Change
Revenue	$11.6M	↑ 1430881.24%
Net Income	$-6.4M	↓ 32.45%
Net Profit Margin	-55.47%	↑ 1174968.09%

	FY22	Y/Y Change
Revenue	$17.0	↓ 100.0%
Net Income	$-17.3M	↑ 192.66%
Net Profit Margin	-98.6M%	↓ 9.859120453E7%

	FY23	Y/Y Change
Revenue	$372.0	↑ 2120.0%
Net Income	$-13.7M	↓ 16.97%
Net Profit Margin	-3.7M%	↑ 9.490384018E7%

	FY24	Y/Y Change
Revenue	$1.5M	↑ 415755.86%
Net Income	$-17.8M	↑ 30.85%
Net Profit Margin	-1.2K%	↑ 3686259.59%

Q1 FY23

Q3 FY23

Q4 FY23

Q3 FY24

	Q1 FY23	Q/Q Change
Revenue	$185.0	-
Net Income	$-2.3M	↓ 74.68%
Net Profit Margin	-1.2M%	-

	Q3 FY23	Q/Q Change
Revenue	$356.0	-
Net Income	$-4.4M	-
Net Profit Margin	-1.2M%	-

	Q4 FY23	Q/Q Change
Revenue	$3.0	↓ 99.1%
Net Income	$-5.9M	↑ 28.26%
Net Profit Margin	-176.5M%	↓ 1.7523077297E8%

	Q3 FY24	Q/Q Change
Revenue	$2.5M	↑ 4.96198E7%
Net Income	$-18.0M	↑ 103.48%
Net Profit Margin	-723.68%	↑ 1.7646953632E8%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$1.1K	↓ 88.06%

	FY20	Y/Y Change
Profit	$731.0	↓ 32.2%

	FY21	Y/Y Change
Profit	$11.6M	↑ 1430881.24%

	FY22	Y/Y Change
Profit	$17.0	↓ 100.0%

	FY23	Y/Y Change
Profit	$372.0	↑ 2120.0%

	FY24	Y/Y Change
Profit	$1.5M	↑ 415755.86%

	Q1 FY23	Q/Q Change
Profit	$185.0	-

	Q3 FY23	Q/Q Change
Profit	$356.0	-

	Q4 FY23	Q/Q Change
Profit	$3.0	↓ 99.1%

	Q3 FY24	Q/Q Change
Profit	$2.5M	↑ 4.96198E7%

FY19

FY20

FY21

FY22

	FY19	Y/Y Change
Operating Cash Flow	$-4.7M	↓ 22.48%
Investing Cash Flow	$1.6M	↑ 1472.67%
Financing Cash Flow	$2.7M	↑ 0.0%

	FY20	Y/Y Change
Operating Cash Flow	$-6.1M	↑ 31.22%
Investing Cash Flow	$-1.6M	↓ 200.24%
Financing Cash Flow	$8.4M	↑ 218.13%

	FY21	Y/Y Change
Operating Cash Flow	$-7.0M	↑ 3.41%
Investing Cash Flow	$-1.8M	↑ 0.0%
Financing Cash Flow	$21.5M	↑ 131.54%

	FY22	Y/Y Change
Operating Cash Flow	$-16.0M	↑ 149.83%
Investing Cash Flow	$-1.7M	↑ 0.0%
Financing Cash Flow	$2.6M	↓ 86.74%

Q4 FY22

Q3 FY23

Q4 FY23

	Q4 FY22	Q/Q Change
Operating Cash Flow	$-5.9M	↓ 22.56%
Investing Cash Flow	$5.0M	↓ 1040.77%
Financing Cash Flow	$3.9M	↑ 57.73%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-4.1M	↑ 100.0%
Investing Cash Flow	$-3.4M	-
Financing Cash Flow	$4.6M	↑ 100.0%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-4.2M	↓ 0.24%
Investing Cash Flow	$3.5M	↓ 200.0%
Financing Cash Flow	$3.2M	↓ 33.26%

Kazia Therapeutics Technicals Summary

Sell

Neutral

Buy

Kazia Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Kazia Therapeutics Ltd Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Kazia Therapeutics Ltd	-22.61%	75.47%	-57.79%	-91.06%	-97.97%
Regeneron Pharmaceuticals, Inc.	4.66%	-17.37%	-50.86%	-2.39%	-3.46%
Beone Medicines Ltd	7.62%	21.35%	57.45%	78.28%	25.05%
Vertex Pharmaceuticals Incorporated	-15.87%	-17.97%	-18.14%	35.67%	45.07%
Alnylam Pharmaceuticals, Inc.	38.16%	82.49%	68.79%	112.36%	238.79%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Kazia Therapeutics Ltd	NA	NA	NA	-0.02	-38.92	-0.86	NA	-3.94
Regeneron Pharmaceuticals, Inc.	15.08	15.08	1.23	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	28.25	28.25	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Kazia Therapeutics Ltd	Buy	$9.9M	-97.97%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$63.4B	-3.46%	15.08	31.37%
Beone Medicines Ltd	NA	$38.2B	25.05%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$101.9B	45.07%	28.25	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	238.79%	NA	-12.96%

About Kazia Therapeutics Ltd

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Organization	Kazia Therapeutics
Employees	0
CEO	Dr. John Edwin Friend II, M.D.
Industry	Health Technology

Key Management of Kazia Therapeutics Ltd

Name	Title
Dr. John Edwin Friend II, M.D.	Chief Executive Officer & MD
Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAIC	Company Secretary
Mr. Jeffrey Bonacorda	VP of Finance & Controller

Important FAQs about investing in KZIA Stock from India :

What is Kazia Therapeutics share price today?

Kazia Therapeutics share price today is $7.73 as on August 23, 2025 at 1:28 AM IST at the close of the market. Kazia Therapeutics share today touched a day high of $7.73 and a low of $7.60.

What is the 52 week high and 52 week low for Kazia Therapeutics share?

Kazia Therapeutics share touched a 52 week high of $39.05 and a 52 week low of $2.86. Kazia Therapeutics stock price today i.e. August 23, 2025 at 1:28 AM IST is closed at $7.73, lower by 80.2% versus the 52 week high.

How to invest in Kazia Therapeutics Stock (KZIA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Kazia Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kazia Therapeutics Shares that will get you 0.1940 shares as per Kazia Therapeutics share price of $7.73 per share as on August 23, 2025 at 1:28 AM IST.

What is the minimum amount required to buy Kazia Therapeutics Stock (KZIA) from India?

Indian investors can start investing in Kazia Therapeutics (KZIA) shares with as little as ₹87.521 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Kazia Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Kazia Therapeutics share’s latest price of $7.73 as on August 23, 2025 at 1:28 AM IST, you will get 1.2937 shares of Kazia Therapeutics. Learn more about fractional shares .

What are the returns that Kazia Therapeutics has given to Indian investors in the last 5 years?

Kazia Therapeutics stock has given -97.97% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?